Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Retained Earnings (2018 - 2025)

Quantum Biopharma's Retained Earnings history spans 8 years, with the latest figure at -$198.3 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 15.21% to -$198.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$198.3 million, a 15.21% decrease, with the full-year FY2025 number at -$198.3 million, down 15.21% from a year prior.
  • Retained Earnings hit -$198.3 million in Q4 2025 for Quantum Biopharma, down from -$195.3 million in the prior quarter.
  • Over the last five years, Retained Earnings for QNTM hit a ceiling of -$100.8 million in Q1 2021 and a floor of -$198.3 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$151.7 million across 5 years, with a median of -$152.7 million in 2023.
  • Biggest five-year swings in Retained Earnings: crashed 63.09% in 2021 and later decreased 4.84% in 2024.
  • Tracing QNTM's Retained Earnings over 5 years: stood at -$126.2 million in 2021, then decreased by 14.28% to -$144.2 million in 2022, then decreased by 8.56% to -$156.5 million in 2023, then dropped by 9.97% to -$172.1 million in 2024, then fell by 15.21% to -$198.3 million in 2025.
  • Business Quant data shows Retained Earnings for QNTM at -$198.3 million in Q4 2025, -$195.3 million in Q3 2025, and -$189.9 million in Q2 2025.